Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
0.7710
-0.0354 (-4.39%)
Oct 7, 2026, 2:08 PM EDT - Market open
Invivyd Employees
Invivyd had 122 employees as of December 31, 2025. The number of employees increased by 22 or 22.00% compared to the previous year. That makes Invivyd the world's 30,134th largest employer and 3,865th in the United States.
Employees
122
Change (1Y)
22
Growth (1Y)
22.00%
Revenue / Employee
$478,402
Profits / Employee
-$879,779
Market Cap
227.26M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 122 | 22 | 22.00% | 122 | 0 |
| Dec 31, 2024 | 100 | 5 | 5.26% | 99 | 1 |
| Dec 31, 2023 | 95 | 9 | 10.47% | 94 | 1 |
| Dec 31, 2022 | 86 | -17 | -16.50% | 84 | 2 |
| Dec 31, 2021 | 103 | - | - | 101 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Sutro Biopharma | 128 |
| Nautilus Biotechnology | 127 |
| InflaRx | 65 |
| Camp4 Therapeutics | 48 |
| Vicore Pharma Holding AB | 46 |
| Q32 Bio | 22 |
| Palisade Bio | 14 |
IVVD News
- 2 days ago - Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Invivyd Phase 3 data supports VYD2311 tolerability, says H.C. Wainwright - TheFly
- 8 days ago - Invivyd Transcript: Study result - Transcripts
- 8 days ago - Invivyd Press release: Study result - Filings
- 8 days ago - Invivyd Slides: Study result - Filings
- 8 days ago - Invivyd announces results from LIBERTY Phase 3 study of VYD2311 - TheFly
- 8 days ago - Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 - GlobeNewsWire
- 15 days ago - These beaten-down stocks could bounce back in January, if history is any guide - Market Watch